Terms: = Sarcomas AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Clinical Outcome
1 results:
1. Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells.
Li D; Mullinax JE; Aiken T; Xin H; Wiegand G; Anderson A; Thorgeirsson S; Avital I; Rudloff U
BMC Cancer; 2018 Jul; 18(1):772. PubMed ID: 30064387
[TBL] [Abstract] [Full Text] [Related]
